Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) EBT Margin (2016 - 2025)

Historic EBT Margin for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 241.07%.

  • NovaBay Pharmaceuticals' EBT Margin changed N/A to 241.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.16%, marking a year-over-year increase of 1064400.0%. This contributed to the annual value of 73.85% for FY2024, which is 183600.0% up from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' EBT Margin stood at 241.07%.
  • In the past 5 years, NovaBay Pharmaceuticals' EBT Margin registered a high of 2.33% during Q4 2024, and its lowest value of 241.07% during Q3 2025.
  • Its 5-year average for EBT Margin is 88.97%, with a median of 77.41% in 2023.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' EBT Margin plummeted by -2202700bps in 2022, and later skyrocketed by 1931900bps in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' EBT Margin stood at 4.98% in 2021, then tumbled by -4424bps to 225.25% in 2022, then rose by 13bps to 195.53% in 2023, then surged by 99bps to 2.33% in 2024, then crashed by -10242bps to 241.07% in 2025.
  • Its EBT Margin was 241.07% in Q3 2025, compared to 2.33% in Q4 2024 and 43.88% in Q2 2024.